Determinants of Opposition Against EPO Patent Grants - The Case of Biotechnology and Pharmaceuticals

Dietmar Harhoff and Markus Reitzig

No 3645, CEPR Discussion Papers from Centre for Economic Policy Research

Abstract: We analyse the determinants of opposition to biotechnology and pharmaceutical patents granted by the European Patent Office between 1978?96. Opposition can be considered an early form of patent validity challenge suit. In our sample, 8.6% of the patents are attacked in opposition proceedings. Using citation and patent family indicators we show that valuable patents are more likely to be attacked, and that opposition is particularly frequent in areas with strong cumulative patent numbers and with high technical or market uncertainty. We comment on the implications of these results for the design of the patent and litigation system

Keywords: Patents; Litigation; Intellectual property rights; European patent office (search for similar items in EconPapers)
JEL-codes: K41 L00 L20 (search for similar items in EconPapers)
Date: 2002-11
New Economics Papers: this item is included in nep-law
References: Add references at CitEc
Citations: View citations in EconPapers (40)

Downloads: (external link)
https://cepr.org/publications/DP3645 (application/pdf)

Related works:
Journal Article: Determinants of opposition against EPO patent grants--the case of biotechnology and pharmaceuticals (2004)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:cpr:ceprdp:3645

Ordering information: This working paper can be ordered from
https://cepr.org/publications/DP3645

Access Statistics for this paper

More papers in CEPR Discussion Papers from Centre for Economic Policy Research 33 Great Sutton Street, London EC1V 0DX, UK.
Bibliographic data for series maintained by CEPR ().